Millennium Management’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $5.41M | Sell |
67,500
-251,000
| -79% | -$20.7M | ﹤0.01% | 2850 |
|
|
2025
Q4 | $27.2M | Sell |
318,500
-247,300
| -44% | -$20.3M | 0.01% | 1275 |
|
|
2025
Q3 | $44M | Buy |
565,800
+507,700
| +874% | +$39.7M | 0.02% | 970 |
|
|
2025
Q2 | $4.54M | Buy |
58,100
+8,200
| +16% | +$612K | ﹤0.01% | 3089 |
|
|
2025
Q1 | $3.62M | Sell |
49,900
-548,600
| -92% | -$39.3M | ﹤0.01% | 3189 |
|
|
2024
Q4 | $44.3M | Buy |
598,500
+200,700
| +50% | +$14M | 0.02% | 861 |
|
|
2024
Q3 | $26.3M | Buy |
397,800
+139,500
| +54% | +$10.1M | 0.01% | 1305 |
|
|
2024
Q2 | $23.9M | Sell |
258,300
-15,200
| -6% | -$1.35M | 0.01% | 1335 |
|
|
2024
Q1 | $26.1M | Sell |
273,500
-128,600
| -32% | -$10.8M | 0.01% | 1321 |
|
|
2023
Q4 | $30.7M | Sell |
402,100
-106,600
| -21% | -$7.42M | 0.01% | 1193 |
|
|
2023
Q3 | $35.2M | Sell |
508,700
-13,800
| -3% | -$1.11M | 0.02% | 954 |
|
|
2023
Q2 | $49.3M | Buy |
522,500
+358,800
| +219% | +$31.2M | 0.02% | 748 |
|
|
2023
Q1 | $13.5M | Buy |
163,700
+113,700
| +227% | +$8.94M | 0.01% | 1676 |
|
|
2022
Q4 | $3.73M | Buy |
50,000
+4,500
| +10% | +$347K | ﹤0.01% | 3050 |
|
|
2022
Q3 | $3.76M | Buy |
45,500
+34,100
| +299% | +$3.28M | ﹤0.01% | 3163 |
|
|
2022
Q2 | $1.08M | Buy |
+11,400
| New | +$1.18M | ﹤0.01% | 4289 |
|
|
2022
Q1 | – | Sell |
-128,100
| Closed | -$16.6M | – | 7056 |
|
|
2021
Q4 | $16.6M | Sell |
128,100
-167,800
| -57% | -$19.6M | 0.01% | 1627 |
|
|
2021
Q3 | $33.5M | Sell |
295,900
-5,000
| -2% | -$571K | 0.02% | 896 |
|
|
2021
Q2 | $31.2M | Buy |
+300,900
| New | +$28.4M | 0.02% | 871 |
|
|
2021
Q1 | – | Sell |
-103,000
| Closed | -$9.4M | – | 6078 |
|
|
2020
Q4 | $9.4M | Sell |
103,000
-21,600
| -17% | -$1.79M | 0.01% | 1808 |
|
|
2020
Q3 | $9.95K | Sell |
124,600
-32,600
| -21% | -$2.54M | 0.01% | 1253 |
|
|
2020
Q2 | $10.9M | Buy |
157,200
+128,100
| +440% | +$9.1M | 0.01% | 1156 |
|
|
2020
Q1 | $1.83M | Sell |
29,100
-264,000
| -90% | -$19M | ﹤0.01% | 2089 |
|
|
2019
Q4 | $22.8M | Sell |
293,100
-308,400
| -51% | -$24.1M | 0.03% | 767 |
|
|
2019
Q3 | $44.1M | Buy |
601,500
+344,700
| +134% | +$24.2M | 0.07% | 358 |
|
|
2019
Q2 | $15.8M | Buy |
256,800
+82,800
| +48% | +$5.01M | 0.02% | 937 |
|
|
2019
Q1 | $11.1M | Buy |
174,000
+129,000
| +287% | +$7.36M | 0.02% | 1175 |
|
|
2018
Q4 | $2.3M | Sell |
45,000
-540,000
| -92% | -$27.3M | ﹤0.01% | 2115 |
|
|
2018
Q3 | $34M | Buy |
585,000
+285,000
| +95% | +$13.9M | 0.04% | 579 |
|
|
2018
Q2 | $14.6M | Buy |
+300,000
| New | +$14M | 0.02% | 1066 |
|
|
2017
Q4 | – | Sell |
-330,000
| Closed | -$12M | – | 3863 |
|
|
2017
Q3 | $12M | Buy |
+330,000
| New | +$12.6M | 0.02% | 1130 |
|
|
2017
Q2 | – | Sell |
-255,000
| Closed | -$8M | – | 3552 |
|
|
2017
Q1 | $8M | Buy |
+255,000
| New | +$7.98M | 0.01% | 1157 |
|
|
2016
Q3 | – | Sell |
-300,000
| Closed | -$9.97M | – | 3340 |
|
|
2016
Q2 | $9.97M | Sell |
300,000
-60,000
| -17% | -$2.05M | 0.02% | 848 |
|
|
2016
Q1 | $10.6M | Buy |
+360,000
| New | +$9.93M | 0.03% | 799 |
|
|
2014
Q4 | – | Sell |
-19,200
| Closed | -$327K | – | 4011 |
|
|
2014
Q3 | $327K | Buy |
+19,200
| New | +$303K | ﹤0.01% | 3029 |
|
|
2014
Q2 | – | Sell |
-69,600
| Closed | -$860K | – | 3539 |
|
|
2014
Q1 | $860K | Sell |
69,600
-271,800
| -80% | -$3.14M | ﹤0.01% | 2312 |
|
|
2013
Q4 | $3.74M | Buy |
341,400
+84,000
| +33% | +$947K | 0.01% | 1381 |
|
|
2013
Q3 | $2.99M | Buy |
257,400
+238,200
| +1,241% | +$2.79M | 0.01% | 1442 |
|
|
2013
Q2 | $215K | Buy |
+19,200
| New | +$227K | ﹤0.01% | 2725 |
|
Other funds holding EW
VCM
VPM
Millennium Management's EW Position: Q1 2026 in Review
Millennium Management reduced its Edwards Lifesciences (EW) stake by 70% in Q1 2026, selling an estimated $353M and leaving 1,796,821 shares worth $144M. The position accounts for 0.06% of the portfolio, ranked #308.
Millennium Management first reported a position in EW in Q2 2013 and has held it in 52 quarters since. The position peaked at $523M in Q2 2025. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.
- Millennium Management held 1,796,821 shares of Edwards Lifesciences worth $144M as of Q1 2026.
- Millennium Management sold 4,284,117 Edwards Lifesciences shares in Q1 2026, an estimated $353M.
- Edwards Lifesciences made up 0.06% of Millennium Management's portfolio in Q1 2026, its #308 holding.
- Millennium Management first reported a position in Edwards Lifesciences in Q2 2013 and has held it in 52 quarters since.
- Millennium Management's Edwards Lifesciences position peaked at $523M in Q2 2025.
- 1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.
Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.